Welcome to our dedicated page for ARDELYX SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARDELYX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARDELYX's regulatory disclosures and financial reporting.
ARDX related reporting person Joseph James Reilly reports the vesting of 10,388 restricted stock units on 05/19/2026 and discloses prior open-market sales of common stock on 02/20/2026 totaling 4,991 shares (4,387 + 602 + 2). The filing lists the issuer as the recipient of vested units for services rendered.
Michael Raab reported multiple dispositions of Common Stock under Rule 144. The filings list sales on 02/20/2026, 02/24/2026, 03/16/2026, and 04/15/2026 with per‑trade share counts and proceeds shown. The excerpt also shows vesting of 108,840 restricted stock units on 05/19/2026.
ARDX submitted a Form 144 reporting an intended transfer related to 7,771 shares of Common Stock tied to the vesting of restricted stock units on 05/19/2026 for services rendered. The filing also lists recent dispositions by John E. Bishop on 02/20/2026 totaling 3,179 shares (2,792; 386; 1) with aggregate proceeds shown.
An insider transaction related to restricted stock units for the issuer was disclosed on 05/19/2026. The filing shows 24,041 shares tied to vesting of restricted stock units and lists prior open-market sales by Laura A. Williams on 02/20/2026 of 7,192 shares and 984 shares for proceeds of $42,181.08 and $5,622.38, respectively. The form reports Common Stock transactions for the account held with Morgan Stanley Smith Barney LLC.
ARDELYX, INC. President & CEO Michael Raab reported an open-market sale and an option exercise involving the company’s common stock. He sold 41,666 shares on May 15, 2026 at a weighted average price of $6.2788 per share under a pre-arranged Rule 10b5-1 trading plan.
On the same date he exercised 20,833 stock options at a strike price of $0.99 per share, receiving the underlying common shares. After these transactions he held 1,814,447 shares of common stock directly and 332,501 stock options, plus indirect holdings of 1,000 and 24,364 shares through family trusts.
Janus Henderson Group plc reports beneficial ownership of 8,371,234 shares of Ardelyx common stock as of 03/31/2026. The filing states this equals 3.4% of the class and that the Asset Managers exercise shared voting and shared dispositive power over those shares. The filing describes the positions as held through multiple Janus Henderson asset‑management entities and includes a statement disclaiming rights to receive dividends or sale proceeds on behalf of those Asset Managers; the filing also notes the Managed Portfolios themselves hold dividend and sale rights and that no single Managed Portfolio owns more than 5% of the class.
State Street Corporation reported beneficial ownership of 13,604,307 shares of Ardelyx, Inc. common stock, representing 5.5% of the class. The filing shows shared voting power of 12,897,628 shares and shared dispositive power of 13,604,307 shares, with ownership reported on behalf of multiple State Street advisory subsidiaries.
Ardelyx, Inc. reported higher Q1 2026 revenue but remains unprofitable as it invests heavily in commercialization and pipeline growth. Total revenues reached $94.5 million, up from $74.1 million, driven mainly by product sales.
Net product sales were $93.4 million, led by IBSRELA at $70.1 million (up 58%) and XPHOZAH at $23.3 million, roughly flat year over year. The company recorded a net loss of $37.6 million, slightly improved from $41.1 million, as operating expenses grew to support marketing and R&D. Ardelyx ended the quarter with $238.1 million in cash, cash equivalents and short-term investments and $203.5 million of long-term debt, and later refinanced its loan facility to extend maturities and lower interest rates.
Ardelyx reported strong first quarter 2026 growth while remaining loss-making. Total product revenue reached $93.4 million for the quarter ended March 31, 2026, up 38% from $67.8 million a year earlier, driven mainly by IBSRELA sales of $70.1 million, which grew 58% year-over-year.
XPHOZAH contributed $23.3 million in revenue, and total revenue including other items was $94.5 million. Operating expenses rose as Ardelyx invested in commercialization and R&D, leading to a net loss of $37.6 million, or $(0.15) per share, slightly improved from a $41.1 million loss a year earlier. The company ended the quarter with $238.1 million in cash, cash equivalents and short-term investments and reiterated 2026 revenue guidance of $410–$430 million for IBSRELA and $110–$120 million for XPHOZAH, while advancing its pipeline, including the Phase 3 ACCEL trial in chronic idiopathic constipation and preclinical candidate RDX10531.